Close
Help
Need Help?





JOURNAL

Clinical Medicine Insights: Oncology

1,027,198 Journal Article Views | Journal Analytics

Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?

Submit a Paper



Publication Date: 07 Nov 2011

Type: Review

Journal: Clinical Medicine Insights: Oncology

Citation: Clinical Medicine Insights: Oncology 2011:5 349-364

doi: 10.4137/CMO.S6087

Abstract

Over the last 6 years, the treatment of metastatic renal cell carcinoma (mRCC) has undergone dramatic changes. A better understanding of the pathogenesis and tumor biology of sporadic renal cell carcinoma has led to the approval of 6 drug regimens: 3 oral multi-targeted tyrosine-kinase inhibitors (sorafenib, sunitinib, and pazopanib), 2 inhibitors of the mammalian target of rapamycin (temsirolimus and everolimus), and 1 monoclonal antibody against the vascular endothelial growth factor (bevacizumab). Pazopanib, a multi-targeted tyrosine kinase inhibitor that targets VEGFR1, 2, and-3; PDGFR- and PDGFR-, and c-Kit, was approved for the treatment of mRCC in October 2009, several years after the other drugs in its class. The efficacy and safety of pazopanib in Phase I, II, and III trials will be examined and its role in mRCC treatment will be described. Future studies that may clarify pazopanib’s role in mRCC will be discussed. Based on pazopanib’s demonstrated efficacy in treatment-naïve and cytokine-refractory patients, along with a seemingly favorable toxicity profile compared with other multi-targeted tyrosine-kinase inhibitors, pazopanib may have a unique niche in the armamentarium of treatment options for mRCC. Results from ongoing studies are awaited to confirm pazopanib’s favorable efficacy-toxicity ratio, especially in comparison with the previous first-line standard-of-care, sunitinib.



Downloads

PDF  (755.93 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML






What Your Colleagues Say About Clinical Medicine Insights: Oncology
I consider that working with you has been the most interesting and friendly process I have experienced publishing.  The staff have been very supportive to me, quickly addressing every concern I had.  The whole process from the arrival of manuscript to the publication is the fastest I´ve ever experienced, and is very convenient for authors.  The staff kept us informed about the whole rigorous process step by step which is a great advantage for us.I ...
Professor Esther Uña Cidón MD PhD (Professor of Oncology/Palliative Medicine, Oncology Department, Clinical University Hospital and Faculty of Medicine of Valladolid, Spain.)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results